Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume 14, Issue 3, Pages 192-205
Publisher
Springer Nature
Online
2011-05-17
DOI
10.1038/pcan.2011.23
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
- (2010) Jean-Christophe Eymard et al. BJU INTERNATIONAL
- Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
- (2010) Giuseppe Di Lorenzo et al. BJU INTERNATIONAL
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Should extrapulmonary small cell cancer be managed like small cell lung cancer?
- (2010) Sinead M. Brennan et al. CANCER
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement
- (2010) R. A. Whipple et al. CANCER RESEARCH
- Reciprocal Activation of Prostate Cancer Cells and Cancer-Associated Fibroblasts Stimulates Epithelial-Mesenchymal Transition and Cancer Stemness
- (2010) E. Giannoni et al. CANCER RESEARCH
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
- (2010) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- Patupilone in cancer treatment
- (2010) Branislav Bystricky et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
- (2010) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
- (2010) J. Zhang et al. JNCI-Journal of the National Cancer Institute
- Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
- (2010) Paul Baas et al. Journal of Thoracic Oncology
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance
- (2010) Hiroshi Tanaka et al. NATURE MEDICINE
- Cabazitaxel
- (2010) Matthew D. Galsky et al. NATURE REVIEWS DRUG DISCOVERY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer
- (2009) C. Serrate et al. ANNALS OF ONCOLOGY
- Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
- (2009) Y. Loriot et al. ANNALS OF ONCOLOGY
- Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
- (2009) Mari Nakabayashi et al. BJU INTERNATIONAL
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
- (2009) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
- (2009) M.-E. Taplin et al. CLINICAL CANCER RESEARCH
- Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
- (2009) R. M. Attar et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- The Role of Androgen Receptor Mutations in Prostate Cancer Progression
- (2009) G. Brooke et al. CURRENT GENOMICS
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
- (2009) S. M. Mumenthaler et al. MOLECULAR CANCER THERAPEUTICS
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
- (2009) G L Semenza ONCOGENE
- Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer
- (2009) A. Sella et al. ONCOLOGY
- Identification of Arrestin2 as a corepressor of androgen receptor signaling in prostate cancer
- (2009) V. Lakshmikanthan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
- (2008) D. R. Berthold et al. ANNALS OF ONCOLOGY
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
- (2008) X. Pivot et al. ANNALS OF ONCOLOGY
- The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data
- (2008) Cristiana Lo Nigro et al. BJU INTERNATIONAL
- Crosstalk between the Androgen Receptor and -Catenin in Castrate-Resistant Prostate Cancer
- (2008) G. Wang et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer
- (2008) C. J. Logothetis et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Androgen receptor and growth factor signaling cross-talk in prostate cancer cells
- (2008) M.-L. Zhu et al. ENDOCRINE-RELATED CANCER
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
- (2008) D. Pchejetski et al. MOLECULAR CANCER THERAPEUTICS
- Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
- (2008) E. Rivera et al. ONCOLOGIST
- Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells
- (2008) Xu-Bao Shi et al. PROSTATE
- Epothilones: tubulin polymerization as a novel target for prostate cancer therapy
- (2008) James J Lee et al. Nature clinical practice. Oncology
- CYP17 inhibition as a hormonal strategy for prostate cancer
- (2008) Alison HM Reid et al. Nature clinical practice. Urology
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
- (2007) Robert W. Ross et al. CANCER
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer
- (2007) Tomasz M. Beer et al. CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now